Correlates of quality of life in ALS: Lessons from the minocycline study

Amyotrophic Lateral Sclerosis

Volumn 11, Issue 1-2, 2010, Pages 116-121

  Lou, Jau Shin ^a   Moore, Dan ^b   Gordon, Paul H ^c   Miller, Robert ^d  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

^d CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

Author keywords

ALSFRS R; Clinical trials; PEG; QoL; Survival

Indexed keywords

MINOCYCLINE; PLACEBO;

AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PREDICTION; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; SURVIVAL RATE; SURVIVAL TIME;

AMYOTROPHIC LATERAL SCLEROSIS; ANTI-BACTERIAL AGENTS; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE PROGRESSION; HUMANS; MINOCYCLINE; OUTCOME ASSESSMENT (HEALTH CARE); PALLIATIVE CARE; PREDICTIVE VALUE OF TESTS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESPIRATORY INSUFFICIENCY; SURVIVAL ANALYSIS;

EID: 77649282138     PISSN: 17482968     EISSN: 1471180X     Source Type: Journal    
DOI: 10.3109/17482960902918719     Document Type: Article

References (21)

1. Rowland LP, Shneider NA. Amyotrophic lateral sclerosis. N Engl J Med. 2001;344:1688-700.
2. Miller R, Michell J, Moore D. Riluzole for amyotrophic lateral sclerosis/motor neuron disease (Cochrane Review). Cochrane Library. Cochrane Database Syst Rev. 2002;2: CD001447.
3. Andersen PM, Borasio GD, Dengler R, Hardiman O, Kollewe K, Leigh PN, et al. EFNS task force on management of amyotrophic lateral sclerosis: guidelines for diagnosing and clinical care of patients and relatives. European Journal of Neurology. 2005;12:921-38.
4. Lou JS, Reeves A, Benice T, Sexton G. Fatigue and depression are associated with poor quality of life in ALS. Neurology. 2003;60:122-3.
5. Goldstein LH, Atkins L, Leigh PN. Correlates of quality of life in people with motor neuron disease (MND). Amyotroph Lateral Scler Other Motor Neuron Disord. 2002;3:123-9.
6. Simmons Z, Bremer BA, Robbins RA, Walsh SM, Fischer S. Quality of life in ALS depends on factors other than strength and physical function. Neurology. 2000;55:388-92.
7. Robbins RA, Simmons Z, Bremer BA, Walsh SM, Fischer S. Quality of life in ALS is maintained as physical function declines. Neurology. 2001;56:442-4.
8. Piepers S, van den Berg JP, Kalmijn S, Van Der PolW,Wokke J, Lindeman E, et al. Effect of non-invasive ventilation on survival, quality of life, respiratory function and cognition: a review of the literature. Amyotroph Lateral Scler. 2006;7:195-200.
9. Mustfa N, Walsh E, Bryant V, Lyall RA, Addington-Hall J, Goldstein LH, et al. The effect of non-invasive ventilation on ALS patients and their caregivers. Neurology. 2006;66: 1211-7.
10. Gordon PH, Moore DH, Miller RG, Florence JM, Verheijde JL, Carolyn Doorish, et al. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomized trial. Lancet Neurol. 2007;6:1045-53.
11. Felgoise SH, Stewart JL, Bremer BA, Walsh SM, Bromberg MB, Simmons Z. The SEIQoL-DW for assessing quality of life in ALS: strengths and limitations. Amyotrophic Lateral Sclerosis, 2009 (in press.)
12. Lyall RA, Donaldson N, Fleming T,Wood C, Newsom-Davis I, Polkey MI, et al. A prospective study of quality of life in ALS patients treated with non-invasive ventilation. Neurology. 2001;57:153-6.
13. Bourke SC, Bullock RE, Williams TL, Shaw PJ, Gibson GJ. Non-invasive ventilation in ALS: indications and effect on quality of life. Neurology. 2003;61:171-7.
14. Jenkinson C, Layte R, Wright L, Coulter A. The UK SF-36: an analysis and interpretation manual. Oxford: Health Services Research Unit, University of Oxford, 1996.
15. Miller RG, Rosenberg JA, Gelinas DF, Mitsumoto H, Newman D, Sufit R, et al. Practice parameter: the care of the patient with amyotrophic lateral sclerosis (an evidence based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. ALS Practice Parameters Task Force. Neurology. 1999;52:1311-23. (Pubitemid 29190518)
16. Miller RG. Examining the evidence on treatment in ALS/ MND. Amyotroph Lateral Scler Other Motor Neuron Disord. 2001;2:3-7.
17. Heffernan C, Jenkinson C, Holmes T, et al. Nutritional management in MND/ALS patients: an evidence based review. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004;5:72-83.
18. Maisey NR, Norman A, Watson M, Allen MJ, Hill ME, Cunningham D. Baseline quality of life predicts survival in patients with advanced colorectal cancer. European Journal of Cancer. 2002;38:1351-7.
19. Karvonen-Gutierrez CA, Ronis DL, Fowler KE, Terell JE, Gruber SB, Duffy SA. Quality of life scores predict survival in patients with head and neck cancer. J Clinical Oncology. 2008;26:2754-60.
20. Aboussouan LS, Khan SU, Meeker DP, Stelmach K, Mitsumoto H. Effect of non-invasive positive-pressure ventilation on survival in amyotrophic lateral sclerosis. Ann Intern Med. 1997;127:450-3.
21. Mitsumoto H, Davidson M, Moore D, Gad N, Brandis M, Ringel S, et al., for the ALS CARE Study Group. Percutaneous endoscopic gastrostomy (PEG) in patients with ALS and bulbar dysfunction. Amyotroph Lateral Scler Other Motor Neuron Disord. 2003;4:177-85.